INSTRUCTIONS TO AUTHORS
The Journal of Molecular Diagnostics, the official journal of the Association for Molecular Pathology (AMP), co-owned by the American Society for Investigative Pathology (ASIP) and published by Elsevier, Inc., seeks to publish high-quality original papers on scientific advances in the field of molecular diagnostics, the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technical advances in the field of molecular diagnostic medicine. The editors welcome for review manuscripts that contain: novel discoveries with direct application to clinical diagnostics or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, clinical informatics, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods which may be applied to diagnosis or monitoring of disease predisposition.Manuscript Categories. In addition to Regular Articles, the Journal also publishes Technical Advances, which are intended to report breakthroughs in methodology or analytical tools applied to molecular diagnostics. Submissions to this category should include a detailed description of the methodological design and discussion of how this technique improves the practice of molecular diagnostics. The Journal also features Reviews, Mini-Reviews, Commentaries, Special Articles, Guest Editorials, and Perspectives solicited by the Editor-in-Chief, as well as AMP meeting abstracts and other articles of interest to the membership of AMP. Authors who wish to publish a Review or Mini-Review should send their curriculum vitae along with an outline of the proposed article for prior approval by the Editor-in-Chief. Reviews have a maximum of 5,000 words, 75 references, and 4 tables or figures (at least one of which is mechanistic). Mini-Reviews have a maximum of 3,000 words, 40 references, and 2 tables or figures (one of which is mechanistic). Commentaries are submitted by invitation only and relate to a concurrently published manuscript. Guest Editorials and Perspectives are published by invitation only.
Review Process. The Editors perform an initial evaluation on all submissions to determine whether they believe the manuscript will achieve a sufficient priority score to warrant publication. Priority is determined by the Editors' assessment of the manuscript relative to other papers being considered. The aim is that expeditious treatment will enable authors to submit their manuscript elsewhere as soon as possible without suffering unnecessary delays. For manuscripts accepted for external review, the Editor-in-Chief assigns manuscripts to Associate Editors according to their expertise. The Associate Editor will solicit reviewers (typically, two external reviews are sought). Authors are encouraged to identify up to five potential reviewers. Authors may also request that specific reviewers not be used due to prior collaborations, known conflicts of interest, or direct competition. The Editors will make every effort to respect requests that are well-founded; however, the Editors do have the authority to utilize such a reviewer if it is necessary for expert peer review. It is the practice of the Journal to conduct a blinded peer-review process. The peer-review process is kept completely confidential; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at firstname.lastname@example.org. The reviewer comments and Associate Editor's recommendation are evaluated by the Editor-in-Chief for disposition and transmittal to the authors. Every effort is made to complete the review process within 30 days of the date received.Review Decisions. Only a portion of manuscripts will be accepted for publication. A number of worthy manuscripts will be rejected based on priority. The Journal will advise authors whether the manuscript is accepted, acceptable with revisions, rejected but encourage resubmission (after major revision), or rejected. A manuscript may be returned to the authors without outside review if the Editors find it inappropriate for publication in this Journal. Appeals (rebuttals) to editorial decisions must be submitted within 60 days to be considered.
Journal Scientific Integrity Policy. The Journal has developed principles for defining proper conduct and scientific misconduct as well as procedures for handling such matters. General guidelines are described below; detailed information can be viewed at http://jmd.amjpathol.org/content/integrity. To report suspected misconduct relating to authors, reviewers, or Editors, send written complaint to the Editorial Office at The Journal of Molecular Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or email@example.com. Issues relating to staff conduct should be directed to the ASIP Executive Officer at the American Society for Investigative Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or firstname.lastname@example.org. Beginning April 1, 2017, the mailing address for JMD will be 1801 Rockville Pike, Rockville, Maryland 20852-9975.Authors
Authorship. Authorship is defined as 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the manuscript or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. When a group serves as a coauthor, the list of members (individuals or institutions) should be included in the Acknowledgements. When submitting a manuscript to the Journal, the corresponding author takes responsibility on behalf of all authors for the authorship, authenticity, and integrity of the research being reported. Any change made to the list of authors (addition, removal, change in order) after manuscript acceptance requires consent of all authors and editorial approval.Author Conduct. Authors should take special care that manuscripts submitted to the Journal are prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see http://www.icmje.org); in particular the ethical considerations regarding authorship, conflicts of interest, redundant publication, and treatment and confidentiality of research subjects should be carefully adhered to. Additionally, the Journal takes great care to secure the confidentiality and integrity of the peer-review process; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at email@example.com. The Editors will consider any deliberate ethical violation in either the reported research or the manuscript preparation and review to be actionable misconduct, the potential results of which may be manuscript rejection or public article retraction, reporting of conduct to the authors' governing institutions, and/or the denial to consider any future submissions to the Journal. Willful misconduct does not include incidents of honest misjudgment or inadvertent error. Detailed information regarding possible misconduct can be found in the Journal Scientific Integrity Policy at http://jmd.amjpathol.org/content/integrity.
Manuscript Submission. Manuscripts should be submitted online via the EVISE system (https://www.evise.com/profile/#/JMDI/login). Detailed instructions on preparing and submitting files can be found on the author submission website at the above URL. Authors having difficulty submitting files online should contact the editorial office for assistance. Manuscript text, figures, tables, and supplemental data files can be emailed to the Editorial Office at firstname.lastname@example.org or sent on disk by mail to: The Journal of Molecular Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993. Beginning April 1, 2017, the mailing address for JMD will be 1801 Rockville Pike, Rockville, Maryland 20852-9975. The cover letter must state any conflicts of interest (both financial and personal), affirm that the manuscript has not been published previously and is not being considered concurrently by another publication, and affirm that all authors and acknowledged contributors have read and approved the manuscript. Submissions will be ineligible for review if previously published in any form (print or online) other than as an abstract. This includes any public posting of raw manuscripts or pre-reviewed material.A non-refundable manuscript processing fee of US$50 is required with submission. This fee should be paid electronically at the time of submission. Manuscripts arising from research in developing countries may be eligible for waiver of the submission fee only if all authors are located in a qualifying country (waiver must be applied for at time of submission; for a list of eligible countries, see Group A and Group B countries at http://www.who.int/hinari/eligibility/en). Otherwise, manuscript submission fees will not be waived.
Manuscript Preparation. Manuscripts should be prepared in the style of the Journal and in accordance with The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see http://www.icmje.org). The preferred file format for text is MS Word. Standard abbreviations can be found in the CSE Style Manual: Scientific Style and Format (8th ed., 2014). All pages of the manuscript should be double-spaced and numbered (including references, tables and figure legends); line numbers should also be included to assist reviewers in making comments. Other formatting specifications (eg, font size and type, margin settings, etc) are left to the authors' discretion, as papers accepted for publication will be reformatted according to the print specifications of the Journal. Manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Authors are encouraged to include a list of nonstandard abbreviations to aid reviewers; however, the Journal does not publish abbreviations or keywords as part of the final article. In addition, authors should be ready to comply with Editors' requests for copies of any similar works in preparation, copies of cited manuscripts that are submitted or in press, and/or supporting manuscript data (eg, data not shown, but summarized in the manuscript) that may aid the review process.Title Page(s). The title page(s) must include a concise title accurately reflecting the findings of the work; full names (not initials) of all authors; department, institution and address where the research was performed; number of text pages, tables and figures; a short running head (40 characters or less); grant numbers and sources of support (including departmental or institutional funding when no extramural funding was received); name, address, phone, fax, and email of the corresponding author; and name and address of author who should receive reprint requests if different from corresponding author. If an author changes employment after the study was performed, the new affiliation information for that author should be included as a footnote. Any relationships (eg, employment, consultancies, board membership, stock ownership, funding, honoraria, expert testimony, patents or royalties, travel reimbursements, industry-supplied free reagents, etc) with any organization or entity having a direct financial or personal interest in the subject matter or materials discussed in the article should also be clearly stated.
Abstract. An abstract of 220 words or less should be prepared on a separate page and should be intelligible to the general reader without reference to the text. The abstract should clearly summarize the background, methodology, results, and significance of the study. Structured abstracts are not Journal style and will need to be revised to eliminate section headings. Abbreviations and citations should be avoided.Text. The remaining sections of the text, which should include Introduction, Materials and Methods, Results, Discussion, and Acknowledgments (in this order), need not begin on new pages. Commonly-abbreviated terms should be spelled out in their first occurrence and then may be referenced in abbreviation through the remainder of the manuscript. The Journal requires the use of official gene and protein symbols, to facilitate standardization of scientific communication. Consult the Human Genome Organisation Gene Nomenclature Committee website (http://www.genenames.org) for gene names and symbols and UniProt (http://www.uniprot.org) for protein names and symbols. For standard mutation nomenclature, refer to Ogino et al, J Mol Diagn 2007 doi:10.2353/jmoldx.2007.060081. For a complete list of other approved nomenclature organizations (eg, bacteria, viruses, mice), please contact the Editorial Office.
For Materials and Methods, authors should describe experimental and statistical methods in enough detail that other researchers can replicate results and evaluate claims. enough detail that other researchers can replicate results and evaluate claims. Authors are encouraged to review the NIH Principles and Guidelines for Reporting Preclinical Research (see http://www.nih.gov/about/reporting-preclinical-research.htm). Inclusion nclusion of method or reagent details as supplementary material is not acceptable. In addition, linking to protocols online is not permissible as there is no guarantee that the information will remain unchanged and accessible in perpetuity. The sequences of oligonucleotides, if not previously published, should be provided. Novel DNA or protein sequences should be deposited to an appropriate database (eg, Genbank, EMBL, SWISS-PROT), with the accession numbers included in the manuscript. When providing supplier information for materials sources, company name and location (city and state, or city and country) should be provided. When describing reagents such as antibodies, cell lines, animal strains, bacteria, and viruses, authors should include the source, characteristics, dilutions, strain, species, sex, authentication, etc. as necessary for repetition of the experiments. Website references to company or commercial information are not permitted. All novel materials and the procedures to prepare them should be described in sufficient detail to allow their reproduction (eg, DNA constructs, analytical software). Materials that are approved for investigational-use only should be clearly indicated. Methods should state whether sample size was determined statistically prior to experimentation, whether samples were randomized (and how), whether data acquisition was blinded (particularly for subjective scoring methodologies), and what criteria were used to include/exclude data points or subjects. Experimental procedures should include the number of replicates performed and the number of samples in each experimental condition. A careful power analysis undertaken at the beginning of work can help assure the significance of study findings. "Discrepant analysis" is regarded as statistically biased and should not be employed for assessment of assay sensitivity and specificity. Reports of assay sensitivity and specificity should include appropriately calculated confidence intervals. Special care should be taken to assure that statistical methods are appropriate, with clearly defined statements of the statistical test(s) used, sample size, and measures reported (eg, mean, median, SD, SEM, confidence intervals). Statistical methods may be assessed by a professional statistician as part of the peer review process.Publication in the Journal implies that the authors agree, upon reasonable request, to share any materials or data that are integral to the results presented in the article, including whatever would be necessary for a skilled investigator to verify or replicate the claims. This may include original software code used in the data analysis. Agreement to share reagents or software code does not preclude the authors from implementing a Data Use Agreement. Authors must disclose upon submission any restrictions on the availability of materials or information, such as for patented or dual-purpose materials. Reporting guidelines for specific study designs (eg, randomized controlled trials) can be found online via the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network (see http://www.equator-network.org/reporting-guidelines). Authors must affirm that the research protocol was approved by the appropriate institutional review boards or ethics committees for human (including use of human cells or tissues) or animal experiments and that all human subjects provided appropriate informed consent and/or that regulations concerning the use of animals in research were adhered to. If race/ethnicity is reported, authors should state who determined race/ethnicity, how the options were defined, and why race/ethnicity was important in the study. Authors should be prepared to provide study protocol number(s) if requested.
Manuscripts that meet the criteria set forth by STARD (Standards for Reporting of Diagnostic Accuracy; http://www.stard-statement.org) will be annotated with a special footnote on the title page. Authors who wish their manuscripts to receive this designation should submit a completed checklist (available at http://www.stard-statement.org/pdf_and_word_documents/Checklist.PDF) at the time of submission for evaluation by the Editors at the time of acceptance.Authors should obtain permission from all individuals named (by full name) in the Acknowledgments who contributed substantially to the work reported (eg, data collection, analysis, or writing/editing assistance) but did not fulfill the authorship criteria. Likewise, authors should receive permission from all individuals named as sources for personal communication or unpublished data. Such permissions should be affirmed by the corresponding author in the cover letter. The list of members of a group author should also be included in this section. A list of individual author contributions may be placed in this section as a separate paragraph. The corresponding author is also encouraged to include a statement of ethical assurance, such as, "X.X. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis."
References. References should begin on a new page, be double-spaced and numbered in order of citation in the text, including citations in tables and figure legends. Citations that first appear in tables, figures, or supplemental data should be numbered according to the item's first call out in the text; a separate reference list should not be prepared for supplemental data. Complete author citation is required (use of "et al" is only acceptable for sources with more than 35 authors). References should conform to the style of the Journal. Examples follow:Journals: Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, Longtine JA, Sabath D, Wang YL: Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms: A Report of the Association for Molecular Pathology. J Mol Diagn 2013, 15:733-744
Electronic Journals: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009, 6:e1000097. http://dx.doi.org/10.1371/journal.pmed.1000097Books: Funkhouser WK: Pathology: The Clinical Description of Human Disease. Edited by Coleman WB and Tsongalis GJ. Burlington, MA, Academic Press, 2010, pp. 137-142
In Press: To be used only for papers accepted for publication. Cite as for journal with (in press) in place of volume and page numbers. Include digital object identifier (doi) when available for online early publications (Epub). Submitted Papers/Unpublished Data: Cite in text only as (unpublished data).Product Inserts: Cite in text only: (Affymetrix technical note: Globin Reduction Protocol: A Method for Processing Whole Blood RNA Samples for Improved Array Results. Santa Clara, CA).
Web sites: Cite in text only. See Data Supplements section below for proper use of web site references. Use the doi when available. Include the name of the institution sponsoring the web site, URL address with direct linkage to the referenced information, and date of last access.Tables. Tables should be typed double-spaced and submitted after the main text on separate pages, as part of the manuscript. The preferred file format for Tables is MS Word; figure file formats (including those embedded in the text) are unacceptable. Tables should be black and white text only and should not include figures or other non-typeset images. Color or gray shading is not permitted. Emphasis may be represented by bold, italics, and underlining. Nucleotide sequences should be capitalized, not lowercase. A summary legend may be included. Table footnotes should use the following sequential symbols: *, †, ‡, §, ∥, ¶ these may be doubled up if needed. All symbols and abbreviations in the table should be defined in the footnotes.
Figures. Authors should give considerable care in preparing figures. Resolution and quality of submitted images is the responsibility of the author; as a routine, the Journal does not provide figure enhancement services. Images (such as graphs and schematics) should have a white background; color, black, or gray is generally unacceptable. Authors are encouraged to carefully consider whether bar or line graphs should be submitted in grayscale or color, paying special attention to the ability of a reader to distinguish between different data points. If figures are to be published in grayscale, they should be submitted for review in grayscale. Authors should refrain from using three-dimensional bars for single sets of data or horizontal lines in graphs. Figures may consist of multiple related panels (labeled A, B, C, etc) described under one figure legend. Each figure (with all of its related panels) should be arranged on a single page, with panels reading from left to right, as it should appear in final publication. Text labels in figures should use a professional looking font such as Arial; Comic Sans should be avoided. Figure labels should appear in the upper left corner as uppercase letters; refrain from using sub-labels (Aa, Ab, Ai, Aii, A1, A2, etc) or titles for each panel label; panels should be labeled chronologically from left to right. Figure panels submitted on separate pages will be arranged at the publisher's discretion. Figures should be sized to fit one column (8 cm) or two columns (17 cm). Maximum page length is 22.5 cm. Figures deviating from these dimensions will be sized at the publisher's discretion. Unwanted background material should be excluded, and edges should be straight.Preparation of Images (Ethics): Taking photographs of the same source under varied fields of view, light intensity, magnifications, or contrast conditions without disclosing that the data are not unique to the present study constitutes suspect scientific conduct. Further, unless serial sections are used, the publication of identical-appearing images labeled with different staining techniques in different papers raises legitimate questions. Finally, reuse of one's data (ie, "self-plagiarism") is a copyright violation if the authors signed over copyright to the publisher; the reuse of such copyrighted images is at the sole discretion of the publisher, with proper attribution of the original publication a requirement of reuse. No specific feature within an image may be enhanced, obscured, moved, removed, or introduced. The grouping of images from different parts of the same gel or blot, or from different gels or blots, fields, or exposures must be made explicit by the arrangement of the figure (eg, using dividing lines) and in the figure legend. Adjustments of brightness, contrast, or color balance are acceptable only if they are applied to the whole image, whether experimental or control image, and as long as they do not obscure or eliminate any information present in the original (Portions adapted with permission from the JCB). Any evidence of inappropriate manipulation may prompt the Editors to request an explanation and access to original data, which the authors must make available. Information can be found in the Journal Scientific Integrity Policy at http://jmd.amjpathol.org/content/integrity.
Digital Art: Digital figure files are required for submission. The Journal of Molecular Diagnostics' requirement for color images is RGB (Red, Green, Blue) color mode. Images submitted in RGB will retain the vivid reds, greens, and blues of the original digital files for online publication. The preferred file formats for digital figures are PDF, TIFF, and EPS. Embedding images in MS Word is strongly discouraged due to loss of resolution. PPT is discouraged due to the potential for font and layout changes occurring after opening in different versions of PowerPoint. For detailed instructions on preparing digital art for submission or production, visit http://www.elsevier.com/wps/find/authorsview.authors/authorartworkinstructions or contact the Editorial Office (email@example.com).Figure Legends. Figure legends should be submitted in a list as part of the manuscript (separate from the figure files) and should describe any staining method and degree of magnification. If the exact scale is critical, scale bars should be used on the photograph and specified in the legend. Figure legends should adequately describe all descriptors: arrows, arrowheads, scale bars, insets, asterisks, boxes/circles/etc in line graphs, and any other notations. Descriptive text, rather than graphics inserted into the text, should be used when possible (eg, closed circles, open boxes, etc); alternatively, a legend key should be included in the figure. Statistical significance (eg, P values) should be clearly defined by asterisks (*, **, ***) or by other sequential symbols: *, †, ‡, §, ¶, || these may be doubled up if needed. P values should be labeled by symbol in the image, with definitions appearing only in the legend (eg, *P < 0.05, **P < 0.01, ***P < 0.001). Labeling of data as not significant (NS) is unnecessary. All abbreviations should also be defined.
* * Data Supplements and Non-Traditional Media. Figures and tables that are critical to the evaluation and understanding of the research presented, but which cannot be accommodated via the print medium (eg, video), will be considered part of the manuscript submission. Details of reagents (ie, oligonucleotides, antibodies) should be part of the main manuscript and not Supplemental Data (see Materials and Methods). Such files will be peer reviewed and published on the Journal website if the manuscript is accepted. Inclusion of supplementary material is at the discretion of the Editors, and data may be moved to the main article at their request. Supplemental figures (PDF, TIFF, or EPS), tables (MS Word or Excel), and legends (MS Word) should be prepared as above. Supplemental material published on the Journal website is subject to the same copyright as applies to the printed article. Online data will remain associated with its article and is not subject to any modifications or updates after publication. As of January 1, 2016, authors of accepted manuscripts are no longer charged for supplemental data being published on the Journal website. However, authors are still encouraged to minimize the size of their supplemental data files.Complex data sets such as microarray data and gene sequences should be deposited in a reliable public archive. Microarray repositories should comply with the Minimum Information About a Microarray Experiment (MIAME) guidelines (http://www.mged.org/Workgroups/MIAME/miame_1.1.html). Examples include Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) and Array Express (http://www.ebi.ac.uk/arrayexpress). Tissue microarray data exchange specifications can be found at http://www.biomedcentral.com/1472-6947/3/5. Otherwise, the data may be published as supplemental data on the Journal's website (http://jmd.amjpathol.org).
Other materials that are not required to understand and evaluate the article may be stored on an institutional website and referenced as a URL within the manuscript text. In this case, the authors must assume responsibility for maintaining a live, unrestricted link to the material from the URL published within the article, in perpetuity. Failure to maintain a live, unrestricted link may result in retraction of the article by the Editors. Material that has been published previously (print or online) is not acceptable for posting as supplementary data. Instead, the appropriate reference(s) to the original publication should be made in the text and references.The Editors will make the final determination as to whether a given data set is essential to the manuscript and whether they will require publication of the material on the Journal website. Failure to relinquish required materials for online publication can result in the reversal of a manuscript's acceptance.
Copyright. Copyright of published manuscripts is held by the Association for Molecular Pathology and the American Society for Investigative Pathology, which must receive the assignment of copyright from the authors of accepted manuscripts. For US government employees, the above assignment applies only to the extent allowed by law. Details regarding copyright transfer and author rights will be presented by Elsevier, Inc., at the time of article production.Authors wishing to republish images, tables, or text previously published elsewhere should provide proof of permission with their submission and should include the appropriate attribution in the figure or table legend or in the text. It is the responsibility of the authors, not the Journal, to obtain such permission from the copyright holder.
Publishing in The Journal of Molecular Diagnostics automatically places authors in compliance with the NIH Public Access Policy (see http://publicaccess. nih.gov/submit_process.htm, Submission Method A). Any article noted as being funded by NIH, Wellcome Trust, MRC, or other groups for which Elsevier, Inc., has a transfer agreement (http://www.elsevier.com/about/open-science/open-access/agreements; such list is subject to change) will be deposited in PubMed Central (PMC), to be made available to the public twelve or six months after final print publication (as stipulated by the funding agency). Authors therefore should NOT complete a separate deposit of their material but will be contacted by PubMed Central for grant verification once the article has been received by the PMC article system. For information on how to cite articles in NIH grant applications, please visit http://www.asip.org/pubs/AuthorNotice.cfm.Contact firstname.lastname@example.org regarding permission to deposit manuscripts in other government-sponsored repositories in cases where The Journal of Molecular Diagnostics does not have a system in place to automatically deposit materials on behalf of its authors. Deposit of accepted or published manuscripts in any non-JMD repository without prior permission by the Journal is a violation of copyright.
Elsevier supports responsible sharing.Find out how you can share your research published in Elsevier journals.Embargo Policy. All information regarding the content of submitted or accepted manuscripts is strictly confidential. Information contained in or about accepted articles cannot appear in print, audio, video, or digital form or be released by the news media until the Journal embargo date has passed, not to exceed the publication date of the article. For detailed information on embargo release dates or for news media requests for preprint copies of specific articles, contact email@example.com.
Financial Disclosure and Conflicts of Interest. All authors must disclose any current or former relationships held by the author or an immediate family member (eg, employment, consultancies, board membership, stock ownership, funding, honoraria, expert testimony, patents or royalties, travel reimbursements, industry-supplied free reagents, etc) with any organization or entity having a direct financial or personal interest in the subject matter or materials discussed in the article. Authors should err on the side of full disclosure and should contact the Editorial Office if they have questions or concerns. This information should be provided at the time of submission and reiterated as part of copyright assignment. Failure to do so may result in manuscript rejection or editorial retraction of the article. Further information can be found in the Journal Scientific Integrity Policy at http://jmd.amjpathol.org/content/integrity. Upon manuscript acceptance, all coauthors will be instructed to formally disclose all potential conflicts.Publication Charges. As of January 1, 2016, there are no longer separate charges for color figures, black & white or grayscale figures, or composed tables. Corresponding authors who are current, dues-paying Regular Members of ASIP at the time of submission will be charged US $80 per page. All other Societies members and nonmembers will be charged US $90 per printed page. Manuscripts arising from research in developing countries may be eligible for waiver of publication charges only if all authors are located in a qualifying country (for a list of eligible countries, see Group A and Group B countries at http://www.who.int/hinari/ eligibility/en). Otherwise, page charges will not be waived, except for solicited editorials.
Approval of Fees and Invoicing: Upon submission of an article, the corresponding author must state their agreement to pay the publications costs, as outlined above. A final invoice will be presented by Elsevier, Inc., immediately after publication; full payment is expected at that time. Failure to pay publication charges may result in the authors' inability to publish future articles in The Journal of Molecular Diagnostics.Open Access. In addition to publication charges outlined above, authors may elect to participate in the Journal's Open Access program. Articles published under Open Access will utilize the Creative Commons (CC) BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0), allowing users to access and share the article easily. CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0) will be made available only when required by the funding agency. All other copyright restrictions regarding reuse still apply. Cost to participate is US$3000, which must be received before article restriction is lifted. Instructions for obtaining Open Access will be presented by Elsevier, Inc., at the time of article production. Authors wishing to participate may also contact the Editorial Office after manuscript acceptance.
Reprints. Reprints should be ordered when page proofs are returned; an order form is included with the proofs. Late reprint orders may result in additional fees. There is no extra charge for color reprints. Author reprints will be supplied in CMYK color mode because it is a printed medium, but electronic reprints will be supplied in RGB color mode for visualization on screen. Each author is eligible to receive one complimentary electronic (secure PDF) reprint. No hardcopy complimentary reprints are provided.Proofs. The corresponding author will be contacted by email once proofs are ready and will be directed to download electronic proofs from a secure website. Electronic page proofs will be provided in RGB, thus reflecting the online quality. Image files will be converted to CMYK for the printed journal; all images published online will be in RGB. Full instructions on completing proof corrections will be provided with the downloaded proof. The author should check the proofs carefully, mark any printer's errors, and answer queries as requested. Author changes should be kept to a minimum. Proof corrections and replacement figures (if any) must be returned within 24 hours to avoid any delay in publication.
Cover Figure. The cover figure is selected by the Editors from illustrations appearing in the issue. Authors are encouraged to suggest a figure for consideration, or include an additional cover figure submission along with their manuscript submission. Cover figures are published at no charge; cover reprints are available as cover stock reprints or posters (http://webshop.elsevier.com/myarticleservices). No complimentary cover reprints are provided.Editorial Communications. All correspondence concerning editorial matters should be addressed to the Editor-in-Chief at The Journal of Molecular Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993, faxed to 301-634-7961, or emailed to firstname.lastname@example.org. Beginning April 1, 2017, the mailing address for JMD will be 1801 Rockville Pike, Rockville, Maryland 20852-9975. Appeals (rebuttals) to editorial decisions must be submitted within 60 days to be considered. Letters to the Editor will be printed at the Editors' discretion in the Correspondence section. The Editors will consider all refutations of previously published work, according to our usual standards of quality, with the original authors given the opportunity to respond to such criticisms. Corrections are published upon request and after editorial review. Retractions are published upon request of authors or their institutions and may also be published by the Journal following a determination of scientific misconduct. Notes of Concern are published in response to editorial concerns relating to scientific or publishing misconduct by authors or reviewers or to alert the scientific community of an ongoing investigation. [Revised: December 2016]